SCHEMBL7144910

SCHEMBL7144910

COc1ccc(-c2c[nH]c(-c3ccc(F)cc3)n2)c(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.54
AMY1A P0DUB6 4/20 0.53
CYP1A1 P04798 1/20 0.46
CYP1B1 Q16678 1/20 0.46
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 1/20 0.43
SQOR Q9Y6N5 2/20 0.41
APP P05067 1/20 0.41
MAPK14 Q16539 2/20 0.41
MAPK13 O15264 1/20 0.41
ALOX5 P09917 1/20 0.41
GCGR P47871 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
ALDH1A3 P47895 2/20 0.40
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7140664 0.90 PDGFRB (0.54) PDGFRBAMY1ANPC1RAB9AMEN1
SCHEMBL29212570 0.86 KMO (0.40) PDGFRB
SCHEMBL8119559 0.85 AURKA (0.43) PDGFRBAMY1ACYP1A1CYP1B1NPC1
SCHEMBL8111883 0.84 PDGFRB (0.47) PDGFRBAMY1ANPC1RAB9AMEN1
Hydrochloric Acid SCHEMBL7140665 0.82 MAPK13 (0.48) PDGFRBCYP1A1CYP1B1NPC1RAB9A
SCHEMBL8124257 0.80 PDGFRB (0.41) PDGFRBNPC1RAB9AMEN1USP2
SCHEMBL30635831 0.79 NPC1 (0.45) PDGFRBCYP1A1CYP1B1NPC1RAB9A
SCHEMBL8123906 0.79 PDGFRB (0.41) PDGFRBCYP1A1CYP1B1NPC1RAB9A
SCHEMBL29212567 0.77 ADORA1 (0.43) PDGFRBNPC1RAB9AMEN1KMT2A
SCHEMBL12111476 0.77 ESR1 (0.48) PDGFRBAMY1ACYP1A1CYP1B1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed